Eli Lilly & Co., the Fortune 500 pharmaceutical company that makes the weight-loss injection Zepbound (tirzepatide), is developing a similar oral drug that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Gam1983/Getty Images
